Ibrance vs Kisqali: Side-by-Side Comparison
Quick answer: Ibrance and Kisqali are both cdk4/6 inhibitor used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Ibrance | Kisqali |
|---|---|---|
| Drug class | CDK4/6 inhibitor | CDK4/6 inhibitor |
| ATC code | L01EF01 | L01EF02 |
| Primary indications | HR-positive HER2-negative advanced breast cancer | HR-positive, HER2-negative advanced or metastatic breast cancer, Early breast cancer (adjuvant) |
| Mechanism | Selective inhibitor of cyclin-dependent kinases 4 and 6, blocking cell cycle progression from G1 to S phase | Ribociclib inhibits cyclin-dependent kinases 4 and 6, halting tumor cell-cycle progression at G1/S |
| Common dose | 125 mg once daily for 21 days followed by 7 days off (28-day cycle) | 600 mg orally once daily, 3 weeks on / 1 week off |
| Detail page | Ibrance details → | Kisqali details → |
How to choose between Ibrance and Kisqali
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All CDK4/6 inhibitor on iMedic · Ibrance full details · Kisqali full details
Frequently asked questions
Is Ibrance better than Kisqali?
Neither is universally 'better.' They are both cdk4/6 inhibitor with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Ibrance to Kisqali?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Ibrance and Kisqali have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Ibrance and Kisqali available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.